Alkem Gets CDSCO Panel Nod To Manufacture, Market Linagliptin, Dapagliflozin antidiabetic FDC Dr. Divya Colin2 Jun 2023 6:00 PM ISTNew Delhi: The drug major Alkem Health Sciences has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Novel triple-drug FDC superior to dual combination in type 2 diabetes patients poorly controlled with metformin Medha Baranwal2 Jun 2023 11:30 AM ISTIndia: A recent study has shown a triple-drug fixed-dose combination (FDC) of sitagliptin + dapagliflozin + metformin ER to be superior to dual...
AstraZeneca gets CDSCO panel nod to Market Dapagliflozin to treat heart failure in adult Dr. Divya Colin31 May 2023 6:00 PM ISTNew Delhi: Pharmaceutical major, AstraZeneca has got a go-ahead from the Subject Expert Committee (SEC) functional under Central Drug Standard Control...
Glenmark gets CDSCO panel nod for Phase III CT of antidiabetic FDC drug Dr. Divya Colin20 May 2023 6:00 PM ISTNew Delhi: Considering the drug major Glenmark's request for bioequivalence (BE) study waiver, the Subject Expert Committee (SEC) functional under...
AstraZeneca Farxiga approved in US to reduce risk of cardiovascular death, hospitalisation for heart failure to broader range of patients Ruchika Sharma10 May 2023 12:30 PM ISTCambridge: AstraZeneca has announced that Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death,...
Dapagliflozin reduces first and recurrent HF hospitalization and CV death: DELIVER trial Medha Baranwal28 April 2023 11:15 AM ISTUSA: Dapagliflozin was shown to reduce the rate of total heart failure events (urgent HF visits and first and subsequent HF hospitalizations) and...
Dapagliflozin benefits heart failure patients regardless of their gout status: JAMA Medha Baranwal27 Feb 2023 10:30 AM ISTUK: A post hoc analysis of 2 trials revealed that dapagliflozin's benefit is consistent in heart failure (HF) patients irrespective of gout. The use...
Sun Pharma Gets CDSCO panel nod to manufacture, market antidiabetic FDC drug Dr. Divya Colin24 Feb 2023 6:00 PM ISTNew Delhi: In a significant development, pharmaceutical major, Sun Pharma has got the go-ahead from the Subject Expert Committee (SEC) functional...
AstraZeneca Forxiga approved in EU for treatment of symptomatic chronic heart failure Ruchika Sharma7 Feb 2023 4:15 PM ISTForxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
Dapagliflozin reduces hospitalization risk in CKD patients regardless of diabetes status Medha Baranwal22 Dec 2022 7:15 AM ISTIsrael: SGLT2 inhibitor dapagliflozin may reduce the hospitalization risk due to any cause in patients with CKD (chronic kidney disease) irrespective...
AstraZeneca Forxiga recommended for nod in EU for chronic heart failure Ruchika Sharma20 Dec 2022 5:30 PM ISTHeart failue is a life-threatening chronic disease in which the heart cannot pump enough blood around the body, affecting 15 million people in the EU.
CDSCO nod to AstraZeneca Pharma Dapagliflozin tablets Ruchika Sharma28 Nov 2022 4:30 PM ISTThe receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded...
